UNMET NEED
As many as 3.3 million individuals in the U.S. live with axial spondyloarthritis (axSpA)1. Of these, approximately half meet the criteria for re-axSpA.2 The FDA recently approved CIMZIA® (certolizumab pegol) to treat adults with active re-axSpA with objective signs of inflammation. This milestone provides an important new treatment option for patients living with this often undiagnosed, chronic, painful and debilitating disease.

C-AXSPAND IS THE FIRST RANDOMIZED, PLACEBO-CONTROLLED STUDY TO FOLLOW ADULT PATIENTS WITH NR-AXSpA OVER 52 WEEKS

**PRIMARY ENDPOINT**

The proportion of patients achieving a major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) defined as ≥2.0 point decrease from baseline.

**FIRST SECONDARY ENDPOINT**

Achievement of the American College of Rheumatology International Society 40% response criteria (ACR40) was evaluated at Weeks 12 and 52.

**RESULTS**

The study met THE PRIMARY ENDPOINT, with significantly more CZP-treated patients demonstrating ASDAS-MI compared to placebo-treated patients.

**COMMON BACKGROUND MEDICATIONS INCLUDE**

- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Corticosteroids
- Antidepressants and non-steroidal anti-inflammatory drugs
- Diuretics
- Calcium channel blockers
- Statins
- Antiplatelet therapy
- Concomitant immunosuppressants such as methotrexate or corticosteroids.

**HEPATITIS B VIRUS REACTIVATION**

Hepatitis B virus (HBV) reactivation has been reported with TNF blockers, including CIMZIA. Patients with a history of HBV infection or HBsAg-positive patients should undergo HBV testing before starting CIMZIA. Consider initiating appropriate therapy.

**IMPORTANT SAFETY INFORMATION**

CIMZIA® is a registered trademark of the UCB Group of Companies.


For full prescribing information, please visit UCB-USA.com.